1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.

KEY BENEFITS
This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell marketDetailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decisionValue chain analysis, Porter’s five forces, top investment pockets are analysed and presented in detail in the reportIntelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisionsSWOT analysis and strategic developments included in the report for Key players: Advanced Cell Technology, Inc. (USA), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.

KEY MARKET SEGMENTS
GLOBAL MARKET, BY STORAGEPublic cord blood banksPrivate cord blood banksPublic Vs. Private UCB banksGLOBAL MARKET, BY DISEASESCancer/ Oncology diseasesAcute LeukemiaChronic LeukemiaHigh Risk Solid TumorsMyelodysplastic SyndromeBlood diseasesAplastic AnemiaBeta ThalassemiaSickle Cell disease     Immune DisordersLeukocyte Adhesion DeficiencyHystiocytic DisordersWiskott-AldrichMetabolic DisordersKrabbe DiseaseHurler SyndromeSanfilippo SyndromeOther diseasesOsteopetrosisHemophagoyticlymphohistiocytosisGLOBAL MARKET BY, TECHNOLOGYStem Cell TransplantAutologous transplantAllogenic transplantTransplant MedicineRegenerative MedicineOthersCord Blood BankingBlood TransfusionCell Based GeneticsGLOBAL MARKET,

BY GEOGRAPHY
UCB market in North AmericaUCB market in EuropeUCB market in Asia-pacificUCB market in ROW

KEY AUDIENCES
Therapeutics service companiesPrivate and government research institutesAcademic InstitutesResearch based pharmaceutical companiesPublic and Private cord blood banks

Table Of Contents

Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020
CHAPTER 1 INTRODUCTIONandnbsp;1.1 Key objectivesandnbsp;1.2 Key benefitsandnbsp;1.3 Key deliverablesandnbsp;1.4 Key audiencesandnbsp;1.5 Research methodologyandnbsp;andnbsp;andnbsp; 1.5.1 Secondary researchandnbsp;andnbsp;andnbsp; 1.5.2 Primary researchandnbsp;andnbsp;andnbsp; 1.5.3 Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARYandnbsp;2.1 Umbilical cord blood stem cell market by Geography , 2012-2020, $millionCHAPTER 3 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEWandnbsp;3.1 Market Descriptionandnbsp;3.2 Market definition and Scopeandnbsp;3.3 Awareness programs for cord blood donationandnbsp;3.4 Key findingsandnbsp;andnbsp;andnbsp; 3.4.1 Top ten factors impacting UCB stem cell marketandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.1 Minimal invasive techniques of collection and transferringandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.2 Efficient extraction of cord bloodandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.3 Storage service for maintaining viabilityandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.4 Government regulation and interventionandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.5 Ethical issues in storage and applicationandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.6 Cost of treatmentandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.7 Availability of treatment and sampleandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.8 Positive engraftment of tissueandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.9 Efficient transferring during treatmentandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.1.10 Reimbursement and insurance issues in storageandnbsp;andnbsp;andnbsp; 3.4.2 Top winning strategiesandnbsp;andnbsp;andnbsp; 3.4.3 Top Investment pocketsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.3.1 UCB stem cell market - by Applicationandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.3.2 UCB market- by Therapeuticsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.4.3.3 UCB market- by Storage serviceandnbsp;3.5 Advantages of umbilical cord blood stem cells over peripheral blood stem cellsandnbsp;3.6 Key advantages of UCB stem cells.andnbsp;andnbsp;andnbsp; 3.6.1 Prompt availabilityandnbsp;andnbsp;andnbsp; 3.6.2 Ease of collectionandnbsp;andnbsp;andnbsp; 3.6.3 More tolerance for graft failureandnbsp;andnbsp;andnbsp; 3.6.4 Reduce risk of Graft vs. host disease (GvHD)andnbsp;andnbsp;andnbsp; 3.6.5 Decreased transmission of viral disease infectionandnbsp;3.7 Regulatory issues, legislations and authorities Reimbursement Issuesandnbsp;andnbsp;andnbsp; 3.7.1 Regulatory issues of UCB stem cells storage and application (U.S.)andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.7.1.1 American Academy of Pediatrics (AAP)andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.7.1.2 American society for Blood and Marrow Transplantation (ASBMT)andnbsp;andnbsp;andnbsp; 3.7.2 Regulatory issues concenringUCB stem cells storage and application in European countriesandnbsp;andnbsp;andnbsp; 3.7.3 Reimbursement issuesandnbsp;3.8 Ethical issues of stem cell therapies and cord blood bankingandnbsp;andnbsp;andnbsp; 3.8.1 Ethical issues regarding cord blood bankingandnbsp;andnbsp;andnbsp; 3.8.2 Ethical issues in cord blood stem cell therapiesandnbsp;3.9 Umbilical cord blood stem cell collection processandnbsp;3.10 UCB Stem cells Storage and collection Outsourcingandnbsp;andnbsp;andnbsp;andnbsp; 3.10.1 Stem cell storage and collection outsourcingandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.10.1.1 Criteria for outsourcing of cord blood storageandnbsp;3.11 Key patents and analysis of Novel Patentsandnbsp;3.12 Clinical trials in UCB stem cell marketandnbsp;andnbsp;andnbsp;andnbsp; 3.12.1 Phase 2 Study of stem cell Educator Therapy in Type 1 Diabetesandnbsp;andnbsp;andnbsp;andnbsp; 3.12.2 Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Childrenandnbsp;andnbsp;andnbsp;andnbsp; 3.12.3 Longitudinal Study of Immune Mediated Disorders After AllogenicHematopoietic Cell Transplantation (HCT)andnbsp;andnbsp;andnbsp;andnbsp; 3.12.4 Evaluation of Hematopoietic and Immunologic Reconstitution after a Reduced-intensity Conditioning Regimenandnbsp;andnbsp;andnbsp;andnbsp; 3.12.5 Umbilical Cord Blood Transplant for Congenital Pediatrics Disordersandnbsp;3.13 Value chain analysis of UCB stem cell marketandnbsp;3.14 Porterandrsquo;s five forces analysis for cord blood stem cell marketandnbsp;andnbsp;andnbsp;andnbsp; 3.14.1 Higher bargaining power of suppliers for getting competitive advantageandnbsp;andnbsp;andnbsp;andnbsp; 3.14.2 Lower bargaining power of buyers in terms of treatmentandnbsp;andnbsp;andnbsp;andnbsp; 3.14.3 Higher degree of competitionandnbsp;andnbsp;andnbsp;andnbsp; 3.14.4 Threats of new entrants increases due to novel therapiesandnbsp;andnbsp;andnbsp;andnbsp; 3.14.5 Increased threats fromconventional therapies and banking substitutesandnbsp;3.15 Market Dynamics of UCB stem cell marketandnbsp;andnbsp;andnbsp;andnbsp; 3.15.1 Market Driversandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.1.1 Minimal invasive methodsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.1.2 Treatment on chronic diseasesandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.1.3 Cost effective therapy and storageandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.1.4 Easy extraction methodsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.1.5 Intact genetic structureandnbsp;andnbsp;andnbsp;andnbsp; 3.15.2 Market Restraintsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.2.1 Government regulations and interventionandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.2.2 Legal and ethical issues during collectionandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.2.3 Availability of right type of donorandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.2.4 Higher cost of therapiesandnbsp;andnbsp;andnbsp;andnbsp; 3.15.3 Market Opportunitiesandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.3.1 Advancement in therapeutic applicationandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.3.2 Rising funds for public storageandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 3.15.3.3 Increase in cost effectiveness to increase APAC market presenceCHAPTER 4 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICEandnbsp;4.1 Difference between Public vs. Private UCB banksandnbsp;andnbsp;andnbsp; 4.1.1 Umbilical cord blood stem cell storage service market ,2012-2020, $millionandnbsp;4.2 Market Driversandnbsp;andnbsp;andnbsp; 4.2.1 Lower cost structureandnbsp;andnbsp;andnbsp; 4.2.2 Immediate availabilityandnbsp;andnbsp;andnbsp; 4.2.3 Government Interventionandnbsp;andnbsp;andnbsp; 4.2.4 Decrease transplant complicationsandnbsp;4.3 Market Restraintsandnbsp;andnbsp;andnbsp; 4.3.1 Long term storageandnbsp;andnbsp;andnbsp; 4.3.2 Lower volume of bloodandnbsp;andnbsp;andnbsp; 4.3.3 Operational Issuesandnbsp;andnbsp;andnbsp; 4.3.4 Legal andamp; Ethical Issuesandnbsp;4.4 Market Opportunitiesandnbsp;andnbsp;andnbsp; 4.4.1 Additional fund collectionandnbsp;andnbsp;andnbsp; 4.4.2 Technological adoptionsandnbsp;andnbsp;andnbsp; 4.4.3 Insurance as USPandnbsp;andnbsp;andnbsp; 4.4.4 Lowering healthcare costsandnbsp;4.5 Public cord blood banksandnbsp;andnbsp;andnbsp; 4.5.1 Cost structure of public cord blood banking:andnbsp;andnbsp;andnbsp; 4.5.2 UCB public storage bank service market , 2012-2020, $millionandnbsp;4.6 Private cord blood banksandnbsp;andnbsp;andnbsp; 4.6.1 UCB private storage bank service market ,2012-2020, $millionCHAPTER 5 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICSandnbsp;5.1 Umbilical cord blood stem cell therapeutics market , 2012-2020, $millionandnbsp;5.2 Market Driversandnbsp;andnbsp;andnbsp; 5.2.1 Fast recoveryandnbsp;andnbsp;andnbsp; 5.2.2 Efficient transferring of stem cellsandnbsp;andnbsp;andnbsp; 5.2.3 Minimum invasive techniqueandnbsp;andnbsp;andnbsp; 5.2.4 Target specificandnbsp;5.3 Market Restraintsandnbsp;andnbsp;andnbsp; 5.3.1 Higher cost of treatmentandnbsp;andnbsp;andnbsp; 5.3.2 Scarcity of donorandnbsp;andnbsp;andnbsp; 5.3.3 Rejection in allogenictransplantationandnbsp;andnbsp;andnbsp; 5.3.4 Difficulty in donor matchingandnbsp;5.4 Opportunitiesandnbsp;andnbsp;andnbsp; 5.4.1 Increasing flexibilityandnbsp;andnbsp;andnbsp; 5.4.2 Improved donor policyandnbsp;andnbsp;andnbsp; 5.4.3 Risk managementandnbsp;5.5 Cancer/ Oncology diseasesandnbsp;andnbsp;andnbsp; 5.5.1 UCB stem cell cancer therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.5.2 UCB stem cell cancer therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.5.3 Acute Leukemiaandnbsp;andnbsp;andnbsp; 5.5.4 UCB stem cell Acute leukemia therapeutics market , 2012-2020,$millionandnbsp;andnbsp;andnbsp; 5.5.5 Chronic Leukemiaandnbsp;andnbsp;andnbsp; 5.5.6 GLOBAL UCB stem cell Chronic leukemia therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.5.7 High risk solid tumoursandnbsp;andnbsp;andnbsp; 5.5.8 Global UCB stem cell high risk solid tumor therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.5.9 Myelodysplastic syndromeandnbsp;andnbsp;andnbsp; 5.5.10 Global UCB stem cell Myleodysplastic syndrome (MDS) therapeutics market , 2012-2020,$millionandnbsp;andnbsp;andnbsp; 5.5.11 Others(chronic myelomonocyticleukemia (CMML))andnbsp;andnbsp;andnbsp; 5.5.12 UCB stem cell other disease therapeutics geography market , 2012-2020, $millionandnbsp;5.6 Diabetesandnbsp;andnbsp;andnbsp; 5.6.1 Global UCB stem cell diabetes therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.6.2 Global UCB stem cell diabetes therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.6.3 Type 1 diabetesandnbsp;andnbsp;andnbsp; 5.6.4 Global UCB stem cell type I diabetes therapeutics geography market, 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.6.5 Type 2 diabetesandnbsp;andnbsp;andnbsp; 5.6.6 UCB stem cell Type II diabetes therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.6.7 Others(Gestational Diabetes Mellitus(GDM))andnbsp;andnbsp;andnbsp; 5.6.8 UCB stem cell Gestational Diabetes Mellitus(GDM) therapeutics geography market , 2012-2020, $millionandnbsp;5.7 Blood diseasesandnbsp;andnbsp;andnbsp; 5.7.1 UCB stem cell blood diseases therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.7.2 UCB stem cell blood diseases therapeutics geography market, 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.7.3 Aplastic Anemiaandnbsp;andnbsp;andnbsp; 5.7.4 Global UCB stem cell Aplastic anemia therapeutics geography market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.7.5 Beta Thalassemiaandnbsp;andnbsp;andnbsp; 5.7.6 Global UCB stem cell Thalassemia therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.7.7 Sickle Cell diseaseandnbsp;andnbsp;andnbsp; 5.7.8 Global UCB stem cell Sickle cell disease therapeutics geography market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.7.9 Others (Iron deficiency anemia)andnbsp;andnbsp;andnbsp; 5.7.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $millionandnbsp;5.8 Immune Disordersandnbsp;andnbsp;andnbsp; 5.8.1 Global UCB stem cell immune disorders therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.8.2 Global UCB stem cell immune disorders therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.8.3 Leukocyte Adhesion Deficiencyandnbsp;andnbsp;andnbsp; 5.8.4 Global UCB stem cell Leukocyte Adhesion deficiency therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.8.5 Hystiocytic disordersandnbsp;andnbsp;andnbsp; 5.8.6 Global UCB stem cell Hystiocytic disorders therapeutics geography market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.8.7 Wiskott-Aldrichandnbsp;andnbsp;andnbsp; 5.8.8 Global UCB stem cell Wiskott-Aldrich therapeutics geography market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.8.9 Others(Inflammatory Bowel Disease (IBD) and Multiple Sclerosis(MS))andnbsp;andnbsp;andnbsp; 5.8.10 Global UCB stem cell others disease therapeutics geography market , 2012-2020, $millionandnbsp;5.9 Metabolic Disordersandnbsp;andnbsp;andnbsp; 5.9.1 Global UCB stem cell metabolic disorders therapeutics market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.9.2 Global UCB stem cell metabolic disorders therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.9.3 Krabbe Diseaseandnbsp;andnbsp;andnbsp; 5.9.4 Global UCB stem cell Krabbe disease therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.9.5 Hurler Syndromeandnbsp;andnbsp;andnbsp; 5.9.6 Global UCB stem cell Hurler syndrome therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.9.7 Sanfilippo Syndromeandnbsp;andnbsp;andnbsp; 5.9.8 Global UCB stem cell Sanfilippo Syndrome therapeutics geography market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.9.9 Others (Fabry disease)andnbsp;andnbsp;andnbsp; 5.9.10 Global UCB stem cell Fabry disease therapeutics geography market , 2012-2020, $millionandnbsp;5.10 Other diseasesandnbsp;andnbsp;andnbsp; 5.10.1 Global UCB stem cell other disease therapeutics market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.10.2 Osteopetrosisandnbsp;andnbsp;andnbsp; 5.10.3 Global UCB stem cell Osteopetrosis disease therapeutics geography market, 2012-2020, $millionandnbsp;andnbsp;andnbsp; 5.10.4 Hemophagoyticlymphohistiocytosis (HLH)andnbsp;andnbsp;andnbsp; 5.10.5 Global UCB stem cell Hemophagoytic lymphohistiocytosis therapeutics geography market , 2012-2020, $millionCHAPTER 6 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATIONandnbsp;6.1 Umbilical cord blood stem cell application market , 2012-2020, $millionandnbsp;6.2 Drivers of UCB stem cell application marketandnbsp;andnbsp;andnbsp; 6.2.1 Auto-repair processandnbsp;andnbsp;andnbsp; 6.2.2 Pre-surgery managementandnbsp;andnbsp;andnbsp; 6.2.3 Disease informationandnbsp;andnbsp;andnbsp; 6.2.4 Positive engraftmentandnbsp;6.3 Restraints of UCB stem cell application marketandnbsp;andnbsp;andnbsp; 6.3.1 Higher cost of treatmentandnbsp;andnbsp;andnbsp; 6.3.2 Genetic variationandnbsp;andnbsp;andnbsp; 6.3.3 Donor Matchingandnbsp;andnbsp;andnbsp; 6.3.4 Ethical problemandnbsp;6.4 Opportunity of UCB stem cell application marketandnbsp;andnbsp;andnbsp; 6.4.1 Cost effective regenerative medicinesandnbsp;andnbsp;andnbsp; 6.4.2 Wound management therapiesandnbsp;andnbsp;andnbsp; 6.4.3 Growing research instituteandnbsp;6.5 Stem Cell Transplantandnbsp;andnbsp;andnbsp; 6.5.1 Global UCB stem cell transplant application market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 6.5.2 Autologous transplantandnbsp;andnbsp;andnbsp; 6.5.3 Global UCB stem cell autologous transplant applicationgeogrpahy market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 6.5.4 Allogenictransplantandnbsp;andnbsp;andnbsp; 6.5.5 Global UCB stem cell allogenic transplant application geography market , 2012-2020, $millionandnbsp;6.6 Transplant Medicineandnbsp;andnbsp;andnbsp; 6.6.1 Global UCB stem cell transplant medicine application geography market , 2012-2020, $millionandnbsp;6.7 Regenerative Medicineandnbsp;andnbsp;andnbsp; 6.7.1 Global UCB stem cell regenerative medicine application geography market , 2012-2020, $millionandnbsp;6.8 Othersandnbsp;andnbsp;andnbsp; 6.8.1 Global UCB stem cell other diseases application market , 2012-2020, $millionandnbsp;andnbsp;andnbsp; 6.8.2 Blood Transfusionandnbsp;andnbsp;andnbsp; 6.8.3 Global UCB stem cell blood tranfusion application geography market 2012-2020, $millionandnbsp;andnbsp;andnbsp; 6.8.4 Cell Based Geneticsandnbsp;andnbsp;andnbsp; 6.8.5 Global UCB stem cell based genetics application geography market , 2012-2020, $millionCHAPTER 7 STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHYandnbsp;7.1 Umbilical cord blood stem cell market by geography , 2012-2020, $millionandnbsp;7.2 UCB stem cell market in North Americaandnbsp;7.3 UCB stem cell market in Europeandnbsp;7.4 UCB stem cell market in Asia-Pacificandnbsp;7.5 UCB market in ROWCHAPTER 8 COMPANY PROFILESandnbsp;8.1 Cytori Therapeutics Inc.andnbsp;andnbsp;andnbsp; 8.1.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.1.2 Company Snapshotandnbsp;andnbsp;andnbsp; 8.1.3 Key Financials of Cytori Therapeutics Inc.andnbsp;andnbsp;andnbsp; 8.1.4 Key Strategies of Cytori Therapeutics Inc.andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.1.4.1 Primary Strategies: Approvalandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.1.4.2 Secondary Strategies: Product Launch and Clinical trialsandnbsp;andnbsp;andnbsp; 8.1.5 SWOT AnalysisofCytori Therapeutics Inc.andnbsp;8.2 Advanced Cell Technology, Inc. (USA)andnbsp;andnbsp;andnbsp; 8.2.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.2.2 Company Snapshotandnbsp;andnbsp;andnbsp; 8.2.3 Key Financials Advanced Cell Technology, Inc. (USA)andnbsp;andnbsp;andnbsp; 8.2.4 Key Strategies Advanced Cell Technology, Inc. (USA)andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.2.4.1 Primary Strategies: Approvalandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.2.4.2 Secondary strategies: Study Reportandnbsp;andnbsp;andnbsp; 8.2.5 SWOT Analysis Advanced Cell Technology, Inc. (USA)andnbsp;8.3 California Stem Cellandnbsp;andnbsp;andnbsp; 8.3.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.3.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.3.3 Key Strategies California Stem Cellandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.3.3.1 Primary Strategies: Approvalandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.3.3.2 Secondary Strategies: Acquisition and clinical trialsandnbsp;andnbsp;andnbsp; 8.3.4 SWOT Analysis of California Stem Cellandnbsp;8.4 Osiris Therapeuticsandnbsp;andnbsp;andnbsp; 8.4.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.4.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.4.3 Key Financials Osiris Therapeuticsandnbsp;andnbsp;andnbsp; 8.4.4 Key Strategies Osiris Therapeuticsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.4.4.1 Primary Strategies: Approvalandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.4.4.2 Secondary strategies: Clinical Trialsandnbsp;andnbsp;andnbsp; 8.4.5 SWOT analysis of Osiris therapeuticsandnbsp;8.5 NeoStem Inc.andnbsp;andnbsp;andnbsp; 8.5.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.5.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.5.3 Key Financials NeoStem Inc.andnbsp;andnbsp;andnbsp; 8.5.4 Key Strategies NeoStem Inc.andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.5.4.1 Primary Strategies: Clinical Trialsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.5.4.2 Secondary Strategies: Collaborationandnbsp;andnbsp;andnbsp; 8.5.5 SWOT AnalysisofNeoStem Inc.andnbsp;8.6 Geron Corporationandnbsp;andnbsp;andnbsp; 8.6.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.6.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.6.3 Key Financials Geron Corporationandnbsp;andnbsp;andnbsp; 8.6.4 Key Strategies Geron Corporationandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.6.4.1 Primary Strategies: Clinical Trials and Investmentandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.6.4.2 Secondary Strategies: Collaborationandnbsp;andnbsp;andnbsp; 8.6.5 SWOT Analysis of Geron Corporationandnbsp;8.7 Opexa Therapeutics, Inc.andnbsp;andnbsp;andnbsp; 8.7.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.7.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.7.3 Key Strategies Opexa Therapeutics, Inc.andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.7.3.1 Primary Strategies: Approvalandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.7.3.2 Secondary Strategies: Agreementandnbsp;andnbsp;andnbsp; 8.7.4 SWOT Analysis of Opexa Therapeutics, Inc.andnbsp;8.8 Athersys, Inc.andnbsp;andnbsp;andnbsp; 8.8.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.8.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.8.3 Key Financials of Athersys, Inc.andnbsp;andnbsp;andnbsp; 8.8.4 Key Strategies Athersys, Inc.andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.8.4.1 Primary Strategies: Clinical Trialsandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.8.4.2 Secondary Strategies: Collaborationandnbsp;andnbsp;andnbsp; 8.8.5 SWOT Analysis Athersys, Inc.andnbsp;8.9 Pluristem Therapeutics Inc.andnbsp;andnbsp;andnbsp; 8.9.1 Company Overviewandnbsp;andnbsp;andnbsp; 8.9.2 Company Snapshot:andnbsp;andnbsp;andnbsp; 8.9.3 Key FinancialsPluristem Therapeutics Inc.andnbsp;andnbsp;andnbsp; 8.9.4 Key Strategies Pluristem Therapeutics Inc.andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.9.4.1 Primary Strategies: Approvalandamp; Clearanceandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.9.4.2 Secondary Strategies: Product Launchandnbsp;andnbsp;andnbsp; 8.9.5 SWOT Analysis of Pluristem Therapeutics Inc.andnbsp;8.10 Mesoblast Limitedandnbsp;andnbsp;andnbsp;andnbsp; 8.10.1 Company Overviewandnbsp;andnbsp;andnbsp;andnbsp; 8.10.2 Company Snapshot:andnbsp;andnbsp;andnbsp;andnbsp; 8.10.3 Key Financials of Mesoblast Limitedandnbsp;andnbsp;andnbsp;andnbsp; 8.10.4 Key Strategies of Mesoblast Limitedandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.10.4.1 Primary Strategies: Acquisitionandnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp;andnbsp; 8.10.4.2 Secondary Strategies: Approvalandnbsp;andnbsp;andnbsp;andnbsp; 8.10.5 SWOT Analysis ofMesoblast LimitedLIST OF TABLES:TABLE 1 andnbsp;UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLIONTABLE 2 andnbsp;DIFFERENCE BETWEEN PERIPHERAL BLOOD AND CORD BLOODTABLE 3 andnbsp;CLINICAL TRIALS PHASE 2 STUDY OF STEM CELL EDUCATOR THERAPY IN TYPE 1 DIABETESTABLE 4 andnbsp;UMBILICAL CORD BLOOD STEM CELL STORAGE SERVICE MARKET ,2012-2020, $MILLIONTABLE 5 andnbsp;PRICING STRUCTURE OF XYTEXCRYO INTERNATIONAL CORD BLOOD BANKTABLE 6 andnbsp;PRICING STRUCTURE OF PARENTandrsquo;S GUIDE TO CORD BLOOD FOUNDATIONTABLE 7 andnbsp;UCB PUBLIC STORAGE BANK SERVICE MARKET , 2012-2020, $MILLIONTABLE 8 andnbsp;PRICING CHART FOR DIFFERENT PRIVATE CORD BLOOD BANKSTABLE 9 andnbsp;UCB PRIVATE STORAGE BANK SERVICE MARKET ,2012-2020, $MILLIONTABLE 10 andnbsp;NUMBER OF TRANSPLANT BY NEW YORK BLOOD CENTER (2009)TABLE 11 andnbsp;EMERGING THERAPIES FROM CORD BLOOD STEM IN CHILDREN (2012)TABLE 12 andnbsp;UMBILICAL CORD BLOOD STEM CELL THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 13 andnbsp;UCB STEM CELL CANCER THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 14 andnbsp;UCB STEM CELL CANCER THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 15 andnbsp;UCB STEM CELL ACUTE LEUKEMIA THERAPEUTICS MARKET , 2012-2020,$MILLIONTABLE 16 andnbsp;GLOBAL UCB STEM CELL CHRONIC LEUKEMIA THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 17 andnbsp;GLOBAL UCB STEM CELL HIGH RISK SOLID TUMOR THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 18 andnbsp;GLOBAL UCB STEM CELL MYLEODYSPLASTIC SYNDROME (MDS) THERAPEUTICS MARKET , 2012-2020,$MILLIONTABLE 19 andnbsp;UCB STEM CELL OTHER DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 20 andnbsp;GLOBAL UCB STEM CELL DIABETES THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 21 andnbsp;GLOBAL UCB STEM CELL DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 22 andnbsp;GLOBAL UCB STEM CELL TYPE I DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 23 andnbsp;UCB STEM CELL TYPE II DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 24 andnbsp;UCB STEM CELL GESTATIONAL DIABETES MELLITUS(GDM) THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 25 andnbsp;UCB STEM CELL BLOOD DISEASES THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 26 andnbsp;UCB STEM CELL BLOOD DISEASES THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLIONTABLE 27 andnbsp;GLOBAL UCB STEM CELL APLASTIC ANEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 28 andnbsp;GLOBAL UCB STEM CELL THALASSEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 29 andnbsp;GLOBAL UCB STEM CELL SICKLE CELL DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 30 andnbsp;GLOBAL UCB STEM CELL OTHERS DIESEA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 31 andnbsp;GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 32 andnbsp;GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 33 andnbsp;GLOBAL UCB STEM CELL LEUKOCYTE ADHESION DEFICIENCY THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 34 andnbsp;GLOBAL UCB STEM CELL HYSTIOCYTIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET 2012-2020, $MILLIONTABLE 35 andnbsp;GLOBAL UCB STEM CELL WISKOTT-ALDRICH THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 36 andnbsp;GLOBAL UCB STEM CELL OTHERS.DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 37 andnbsp;GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 38 andnbsp;GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 39 andnbsp;GLOBAL UCB STEM CELL KRABBE DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 40 andnbsp;GLOBAL UCB STEM CELL HURLER SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 41 andnbsp;GLOBAL UCB STEM CELL SANFILIPPO SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 42 andnbsp;GLOBAL UCB STEM CELL FABRY DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 43 andnbsp;GLOBAL UCB STEM CELL OTHER DISEASE THERAPEUTICS MARKET , 2012-2020, $MILLIONTABLE 44 andnbsp;GLOBAL UCB STEM CELL OSTEOPETROSIS DISEASE THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLIONTABLE 45 andnbsp;GLOBAL UCB STEM CELL HEMOPHAGOYTIC LYMPHOHISTIOCYTOSIS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 46 andnbsp;UMBILICAL CORD BLOOD STEM CELL APPLICATION MARKET , 2012-2020, $MILLIONTABLE 47 andnbsp;GLOBAL UCB STEM CELL TRANSPLANT APPLICATION MARKET , 2012-2020, $MILLIONTABLE 48 andnbsp;GLOBAL UCB STEM CELL TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 49 andnbsp;GLOBAL UCB STEM CELL AUTOLOGOUS TRANSPLANT APPLICATIONGEOGRPAHY MARKET , 2012-2020, $MILLIONTABLE 50 andnbsp;GLOBAL UCB STEM CELL ALLOGENIC TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 51 andnbsp;GLOBAL UCB STEM CELL TRANSPLANT MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 52 andnbsp;GLOBAL UCB STEM CELL REGENERATIVE MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 53 andnbsp;GLOBAL UCB STEM CELL OTHER DISEASES APPLICATION MARKET , 2012-2020, $MILLIONTABLE 54 andnbsp;GLOBAL UCB STEM CELL BLOOD TRANFUSION APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 55 andnbsp;GLOBAL UCB STEM CELL BASED GENETICS APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLIONTABLE 56 andnbsp;COMPARATIVE ANALYSIS OF MARKET BY GEOGRAPHYTABLE 57 andnbsp;UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLIONTABLE 58 andnbsp;CYTORI THERAPEUTICS INC(USA) COMPANY SNAPSHOTTABLE 59 andnbsp;ADVANCED CELL TECHNOLOGIES INC. COMPANY SNAPSHOTTABLE 60 andnbsp;CALIFORNIA STEM CELL INC. COMPANY SNAPSHOTTABLE 61 andnbsp;OSIRIS THERAPEUTICS COMPANY SNAPSHOTTABLE 62 andnbsp;NEOSTEM INC COMPANY SNAPSHOTTABLE 63 andnbsp;GERON CORPORATION COMPANY SNAPSHOTTABLE 64 andnbsp;OPEXA THERAPEUTICS, INC. COMPANY SNAPSHOTTABLE 65 andnbsp;ATHERSYS INC. COMPANY SNAPSHOTTABLE 66 andnbsp;PLURISTEM THERAPEUTICS INC. COMPANY SNAPSHOTTABLE 67 andnbsp;MESOBLAST LIMITED COMPANY SNAPSHOTLIST OF FIGURES:FIG. 1andnbsp;andnbsp; andnbsp;SUCCESS RATE FOR UCB STEM CELL TRANSPLANT BASED ON TYPE OF DONORS (2012)FIG. 2andnbsp;andnbsp; andnbsp;UCB STEM CELL MARKET DEFINITIONFIG. 3andnbsp;andnbsp; andnbsp;PERCENTAGE OF WOMEN TAKING PRESCRIPTION BY PHYSICIANS (2007-2012)FIG. 4andnbsp;andnbsp; andnbsp;FACTORS IMPACTING ON UCB STEM CELL MARKETFIG. 5andnbsp;andnbsp; andnbsp;TOP WINING STRATEGIES FOR UCB STEM CELL MARKET FROM 2008-2013FIG. 6andnbsp;andnbsp; andnbsp;TOP INVESTMENT POCKETS IN UCB CORD BLOOD STEM CELL APPLICATION MARKET (2012-2020)FIG. 7andnbsp;andnbsp; andnbsp;PERCENTAGE COMPARISON OF CAGR IN THERAPEUTICS MARKETFIG. 8andnbsp;andnbsp; andnbsp;PERCENTAGE COMPARISON OFandnbsp; CAGR IN STORAGE SERVICE MARKETFIG. 9andnbsp;andnbsp; andnbsp;CORD BLOOD STEM CELL COLLECTION PROCEDUREFIG. 10andnbsp;andnbsp; andnbsp;KEY PATENTS FOR UCB STEM CELL FROM 2008-2013FIG. 11andnbsp;andnbsp; andnbsp;PATENT ANALYSIS FROM 2008-2013FIG. 12andnbsp;andnbsp; andnbsp;VALUE CHAIN ANALYSIS OF UCB STEM CELL MARKETFIG. 13andnbsp;andnbsp; andnbsp;PORTER FIVE FORCE MODEL FOR CORD BLOOD STEM CELL MARKETFIG. 14andnbsp;andnbsp; andnbsp;IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS IN UCB STEM CELL MARKETFIG. 15andnbsp;andnbsp; andnbsp;CORD BLOOD UNITS ON THE MATCH REGISTRY (2013)FIG. 16andnbsp;andnbsp; andnbsp;GROWTH IN DISEASE TREATED VS. CLINICAL TRIALS (2008-2012)FIG. 17andnbsp;andnbsp; andnbsp;AGE GROUP TREATED WITH CORD BLOOD STEM CELL THERAPIESFIG. 18andnbsp;andnbsp; andnbsp;TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011FIG. 19andnbsp;andnbsp; andnbsp;CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012FIG. 20andnbsp;andnbsp; andnbsp;SUBTYPES OF LEUKEMIA CASES IN CHILDREN WORLD-WIDE (2013)FIG. 21andnbsp;andnbsp; andnbsp;CHRONIC DISEASE BURDEN 2003-2023 ($ BILLIONS)FIG. 22andnbsp;andnbsp; andnbsp;NUMBER OF AMERICANS WITH CHRONIC DISEASES(FORECASTED)FIG. 23andnbsp;andnbsp; andnbsp;TREATMENT THERPAIES ON DIABETES, 2011FIG. 24andnbsp;andnbsp; andnbsp;PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY,IN 2012(IN THOUSANDS)FIG. 25andnbsp;andnbsp; andnbsp;GLOBAL PREVALENCE OFTYPE-2 DIABETES IN 2000 andamp;ESTIMATED PREVALENCE IN 2030FIG. 26andnbsp;andnbsp; andnbsp;SINGAPORE CORD BLOOD BANK INVENTORY AND TRANSPLANT (2005-2013)FIG. 27andnbsp;andnbsp; andnbsp;STEM CELL TRANSPLANT BY CELL SOURCE IN CHILDREN BELOW 18 YEARSFIG. 28andnbsp;andnbsp; andnbsp;IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS OF UCB STEM CELL APPLICATION MARKETFIG. 29andnbsp;andnbsp; andnbsp;EMERGING APPLICATION OF CORD BLOOD UNITS IN 2012FIG. 30andnbsp;andnbsp; andnbsp;TRANSFORMATION OF CORD BLOOD STEM CELL APPLICATION IN REGENERATIVE MEDICINE APPLICATIONFIG. 31andnbsp;andnbsp; andnbsp;GROWTH RATE COMPARISON FOR UCB STEM CELLGEOGRAPHY MARKET (2013-2020)FIG. 32andnbsp;andnbsp; andnbsp;U.S. FEDRAL SPENDING -FISCAL YEAR 2012FIG. 33andnbsp;andnbsp; andnbsp;CONCENTRATION OF EUROPEAN STEM CELL THERAPY FIRMSFIG. 34andnbsp;andnbsp; andnbsp;TOTAL CELL THERAPIES BY TYPES IN EUROPEAN COUNTRIESFIG. 35andnbsp;andnbsp; andnbsp;DISEASES FACED OR IN FAMILY MEMBERS IN CHINAFIG. 36andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OF CYTORI THERAPEUTICS INC.FIG. 37andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OF ADVANCED CELL TECHNOLOGY, INC. (USA)FIG. 38andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OF CALIFORNIA STEM CELLFIG. 39andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OSIRIS THERAPEUTICSFIG. 40andnbsp;andnbsp; andnbsp;SWOT ANALYSISOFNEOSTEM INC.FIG. 41andnbsp;andnbsp; andnbsp;SWOT ANALYSISOFGERONCORPORATIONFIG. 42andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OF OPEXA THERAPEUTICS, INCFIG. 43andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OF ATHERSYS, INC.FIG. 44andnbsp;andnbsp; andnbsp;SWOT ANALYSIS OF PLURISTEM THERAPEUTICS INC.FIG. 45andnbsp;andnbsp; andnbsp;SWOT ANALYSIS FOR MESOBLAST LIMITED

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Stem Cell Assay Market by Type, Kit, Product, Application, End User - Forecast to 2021

Stem Cell Assay Market by Type, Kit, Product, Application, End User - Forecast to 2021

  • $ 6328
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021. Factors such as high prevalence of chronic diseases, ...

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Regenerative medicines are capable of restoring the functionality of cells & tissues by treating a patient with laboratory grown cells and tissues. Regenerative medicines are used in a wide range of degenerative ...

Stem Cell Therapies Market: By Therapy (Autologous & Allogeneic), By Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) & By Geography -Forecast (2016-2021)

Stem Cell Therapies Market: By Therapy (Autologous & Allogeneic), By Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Stem-cell therapy medical practice which is used to treat or prevent a disease or condition using stem cells.Recent inventions and R&D activities have shown that stem cells have tremendous promise to help ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.